Sign In
Buy IMTX
$10.21
+0.165 (+1.64%)
At Close: Jun 03, 2026
Immatics: PRAME Leader's Transition To Commercial Reality
12:04am, Thursday, 25'th Dec 2025
Immatics executes a three-wave strategy, progressing from melanoma treatment to broader solid tumors and scalable bispecific TCR therapeutics. IMTX's $505.8M cash position funds operations through 202
Houston , Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in pre
Immatics Announces $125 Million Underwritten Offering
06:00am, Friday, 05'th Dec 2025
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in pr
Immatics (NASDAQ:IMTX) Sets New 12-Month High – Here’s What Happened
04:14am, Friday, 05'th Dec 2025
Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price hit a new 52-week high on Friday. The stock traded as high as $12.41 and last traded at $11.87, with a volume of 1011398 shares. The stock
Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of “Moderate Buy” from Brokerages
03:58am, Wednesday, 19'th Nov 2025
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat reports. One equ
Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates
09:16am, Monday, 17'th Nov 2025
Immatics (IMTX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.12 per share a year ago.
Immatics Announces Third Quarter 2025 Financial Results and Business Update
07:00am, Monday, 17'th Nov 2025
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will o
Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET
Immatics Appoints Amie Krause as Chief People Officer
07:00am, Monday, 27'th Oct 2025
Houston , Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in prec
Houston , Texas and Tuebingen, Germany, October 20, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in prec
Immatics: Multiple Clinical Catalysts In Q4'25 And 2026
10:25am, Friday, 10'th Oct 2025
IMTX is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Anzu-cel offers advantages over IOVA's Amtagvi, including less invasive cell collectio
New Strong Sell Stocks for August 15th
07:16am, Monday, 18'th Aug 2025
IMTX, ERJ and BFIN have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2025.
Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates
09:15am, Wednesday, 13'th Aug 2025
Immatics (IMTX) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.18 per share a year ago.
Immatics Announces Second Quarter 2025 Financial Results and Business Update
07:00am, Wednesday, 13'th Aug 2025
Houston, Texas and Tuebingen, Germany, August 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precis
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
10:56am, Tuesday, 03'rd Jun 2025
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
